Takeda engaged in anticompetitive scheme regarding Amitiza, US jury finds
MLex Summary: Takeda Pharmaceuticals engaged in an unlawful scheme to delay generic competition for its name-brand drug Amitiza, according to a US federal jury verdict. See attached file....To view the full article, register now.
Already a subscriber? Click here to view full article